Background Preoperative locoregional treatment (LRT) for hepatocellular carcinoma (HCC) often induces intratumoral necrosis without affecting the overall tumor size, and residual viable tumor size (VTS) on imaging is an important clinical parameter for assessing post-treatment response. However, for surgical specimens, it is unclear whether the VTS would be more relevant to prognosis compared to total tumor size (TTS).
Methods A total of 142 surgically resected solitary HCC cases were retrospectively reviewed. The TTS and VTS were assessed by applying the modified Response Evaluation Criteria in Solid Tumors method to the resected specimens, and correlated with the clinicopathological features and survival.
Results As applying VTS, 13/142 cases (9.2%) were down-staged to ypT1a. Although the survival analysis results for overall survival according to TTS or VTS were similar, VTS was superior to predict disease-free survival (DFS; p = .023) compared to TTS (p = .08). In addition, multivariate analysis demonstrated VTS > 2 cm to be an independent predictive factor for decreased DFS (p = .001). In the subpopulation of patients with LRT (n = 54), DFS in HCCs with TTS or VTS > 2 cm were significantly shorter than those with TTS or VTS ≤ 2 cm (p = .047 and p = .001, respectively). Interestingly, HCCs with TTS > 2 cm but down-staged to VTS ≤ 2 cm after preoperative LRT had similar survival to those with TTS ≤ 2 cm.
Conclusions Although the prognostic impact of tumor size was similar regardless of whether TTS or VTS was applied, reporting VTS may help to increase the number of candidates for surgery in HCC patients with preoperative LRT.
Citations
Citations to this article as recorded by
Measures for response assessment in HCC treatment Fereshteh Yazdanpanah, Omar Al-Daoud, Moein Moradpour, Stephen Hunt Hepatoma Research.2024;[Epub] CrossRef
Machine Learning for Dynamic Prognostication of Patients With Hepatocellular Carcinoma Using Time-Series Data: Survival Path Versus Dynamic-DeepHit HCC Model Lujun Shen, Yiquan Jiang, Tao Zhang, Fei Cao, Liangru Ke, Chen Li, Gulijiayina Nuerhashi, Wang Li, Peihong Wu, Chaofeng Li, Qi Zeng, Weijun Fan Cancer Informatics.2024;[Epub] CrossRef
Construction and validation of a novel signature based on epithelial-mesenchymal transition–related genes to predict prognosis and immunotherapy response in hepatocellular carcinoma by comprehensive analysis of the tumor microenvironment Biao Gao, Yafei Wang, Shichun Lu Functional & Integrative Genomics.2023;[Epub] CrossRef
Cellular senescence affects energy metabolism, immune infiltration and immunotherapeutic response in hepatocellular carcinoma Biao Gao, Yafei Wang, Shichun Lu Scientific Reports.2023;[Epub] CrossRef
Hepatocellular adenoma: what we know, what we do not know, and why it matters Paulette Bioulac‐Sage, Annette S H Gouw, Charles Balabaud, Christine Sempoux Histopathology.2022; 80(6): 878. CrossRef
Hepatocellular adenomas: recent updates Haeryoung Kim, Young Nyun Park Journal of Pathology and Translational Medicine.2021; 55(3): 171. CrossRef
Background Recently, molecular classifications of gastric cancer (GC) have been proposed that include TP53 mutations and their functional activity. We aimed to demonstrate the correlation between p53 immunohistochemistry (IHC) and TP53 mutations as well as their clinicopathological significance in GC.
Methods Deep targeted sequencing was performed using surgical or biopsy specimens from 120 patients with GC. IHC for p53 was performed and interpreted as strong, weak, or negative expression. In 18 cases (15.0%) with discrepant TP53 mutation and p53 IHC results, p53 IHC was repeated.
Results Strong expression of p53 was associated with TP53 missense mutations, negative expression with other types of mutations, and weak expression with wild-type TP53 (p<.001). The sensitivity for each category was 90.9%, 79.0%, and 80.9%, and the specificity was 95.4%, 88.1%, and 92.3%, respectively. The TNM stage at initial diagnosis exhibited a significant correlation with both TP53 mutation type (p=.004) and p53 expression status (p=.029). The Kaplan-Meier survival analysis for 109 stage II and III GC cases showed that patients with TP53 missense mutations had worse overall survival than those in the wild-type and other mutation groups (p=.028). Strong expression of p53 was also associated with worse overall survival in comparison to negative and weak expression (p=.035).
Conclusions Results of IHC of the p53 protein may be used as a simple surrogate marker of TP53 mutations. However, negative expression of p53 and other types of mutations of TP53 should be carefully interpreted because of its lower sensitivity and different prognostic implications.
Citations
Citations to this article as recorded by
Multiple approaches revealed MGc80‐3 as a somatic hybrid with HeLa cells rather than a gastric cancer cell line Fang Cao, Hao Sun, Zhenli Yang, Yanhua Bai, Xiao Hu, Yuhong Hou, Xiaocui Bian, Yuqin Liu International Journal of Cancer.2024; 154(1): 155. CrossRef
In Response to p53 Immunohistochemical Staining and TP53 Gene Mutations in Endometrial Cancer: Does Null Pattern Correlate With Prognosis? Ikuko Sakamoto, Keiko Kagami, Takahiro Nozaki, Yosuke Hirotsu, Kenji Amemiya, Toshio Oyama, Masao Omata American Journal of Surgical Pathology.2024; 48(3): 374. CrossRef
CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function Carolina Pires, Inês J. Marques, Mariana Valério, Ana Saramago, Paulo E. Santo, Sandra Santos, Margarida Silva, Margarida M. Moura, João Matos, Teresa Pereira, Rafael Cabrera, Diana Lousa, Valeriano Leite, Tiago M. Bandeiras, João B. Vicente, Branca M. Ca Journal of Biological Chemistry.2024; 300(3): 105767. CrossRef
The spectrum of TP53 mutations in Rwandan patients with gastric cancer Augustin Nzitakera, Jean Bosco Surwumwe, Ella Larissa Ndoricyimpaye, Schifra Uwamungu, Delphine Uwamariya, Felix Manirakiza, Marie Claire Ndayisaba, Gervais Ntakirutimana, Benoit Seminega, Vincent Dusabejambo, Eric Rutaganda, Placide Kamali, François Ngab Genes and Environment.2024;[Epub] CrossRef
Gastric cancer molecular classification based on immunohistochemistry and in‐situ hybridisation and mortality Maarit Eskuri, Eva‐Maria Birkman, Joonas H Kauppila Histopathology.2024; 85(2): 327. CrossRef
Redefining aberrant P53 expression of gastric cancer and its distinct clinical significance among molecular-histologic subtypes Shih-Chiang Huang, Ian Yi-Feng Chang, Tse-Ching Chen, Hsiao-Ching Lin, Chun-Yi Tsai, Jun-Te Hsu, Chun-Nan Yeh, Shih-Cheng Chang, Ta-Sen Yeh Asian Journal of Surgery.2024; 47(11): 4699. CrossRef
Assessment of TP53 and CDKN2A status as predictive markers of malignant transformation of sinonasal inverted papilloma Soohyeon Kwon, Jeong-Whun Kim, Eun Sun Kim, Jin Ho Paik, Jin-Haeng Chung, Sung-Woo Cho, Tae-Bin Won, Chae-Seo Rhee, Jee Hye Wee, Hyojin Kim Scientific Reports.2024;[Epub] CrossRef
Implementing an integrated molecular classification for gastric cancer from endoscopic biopsies using on-slide tests Simona Costache, Adelina Baltan , Sofia Diaz McLinn , Mattia Pegoraro , Rebecca de Havilland , Matthew Porter , Ana Lerga , Teresa Thomas , Alina Elena Chefani Romanian Journal of Morphology and Embryology.2024; 65(2): 257. CrossRef
Application of NGS molecular classification in the diagnosis of endometrial carcinoma: A supplement to traditional pathological diagnosis Qunxian Rao, Jianwei Liao, Yangyang Li, Xin Zhang, Guocai Xu, Changbin Zhu, Shengya Tian, Qiuhong Chen, Hui Zhou, Bingzhong Zhang Cancer Medicine.2023; 12(5): 5409. CrossRef
Predictive value of p53 and AXL immunostaining for the efficacy of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with epidermal growth factor-mutant non-small cell lung cancer Kenji Morimoto, Tadaaki Yamada, Ryo Sawada, Koichi Azuma, Yasuhiro Goto, Taishi Harada, Shinsuke Shiotsu, Nobuyo Tamiya, Yusuke Chihara, Takayuki Takeda, Osamu Hiranuma, Isao Hasegawa, Satomi Tanaka, Akihiro Yoshimura, Masahiro Iwasaku, Shinsaku Tokuda, Y Cancer Immunology, Immunotherapy.2023; 72(6): 1699. CrossRef
Validation of p53 Immunohistochemistry (PAb240 Clone) in Canine Tumors with Next-Generation Sequencing (NGS) Analysis Barbara Brunetti, Dario de Biase, Giulia Dellapina, Luisa Vera Muscatello, Francesco Ingravalle, Giorgia Tura, Barbara Bacci Animals.2023; 13(5): 899. CrossRef
Mesonephric‐like adenocarcinoma of the female genital tract: novel observations and detailed molecular characterisation of mixed tumours and mesonephric‐like carcinosarcomas Jelena Mirkovic, Ekaterina Olkhov‐Mitsel, Yutaka Amemiya, Maysa Al‐Hussaini, Sharon Nofech‐Mozes, Bojana Djordjevic, Rachel Kupets, Arun Seth, W Glenn McCluggage Histopathology.2023; 82(7): 978. CrossRef
Clinicopathologic characterization of cervical metastasis from an unknown primary tumor: a multicenter study in Korea Miseon Lee, Uiree Jo, Joon Seon Song, Youn Soo Lee, Chang Gok Woo, Dong-Hoon Kim, Jung Yeon Kim, Sun Och Yoon, Kyung-Ja Cho Journal of Pathology and Translational Medicine.2023; 57(3): 166. CrossRef
P53 in Penile Squamous Cell Carcinoma: A Pattern-Based Immunohistochemical Framework with Molecular Correlation Isabel Trias, Adela Saco, Lorena Marimon, Ricardo López del Campo, Carolina Manzotti, Oriol Ordi, Marta del Pino, Francisco M. Pérez, Naiara Vega, Silvia Alós, Antonio Martínez, Leonardo Rodriguez-Carunchio, Oscar Reig, Pedro Jares, Cristina Teixido, Tare Cancers.2023; 15(10): 2719. CrossRef
p53/TP53 Status Assessment in Gastroesophageal Adenocarcinoma Elisa Boldrin, Maria Assunta Piano, Francesco Bernaudo, Rita Alfieri, Maria Raffaella Biasin, Isabella Monia Montagner, Alice Volpato, Genny Mattara, Francesco Lamacchia, Giovanna Magni, Antonio Rosato, Antonio Scapinello, Pierluigi Pilati, Matteo Curtare Cancers.2023; 15(10): 2783. CrossRef
Genomic profiling of dedifferentiated endometrial carcinomas arising in the background of high‐grade carcinoma: a targeted next‐generation sequencing study Ekaterina Olkhov‐Mitsel, Aurelia Busca, Carlos Parra‐Herran, Yutaka Amemiya, Sharon Nofech‐Mozes, Bojana Djordjevic, Marisa R Nucci, Arun Seth, Jelena Mirkovic Histopathology.2023; 83(3): 366. CrossRef
Clinicopathologic Features and Prognostic Significance of Immunohistochemistry and In Situ Hybridization Based Molecular Classification in Gastric Carcinoma
Gizem Issin, İlyas Sayar, Fatih Demir, İrem Güvendir Bakkaloğlu, Mehmet Gamsizkan, Zeliha Yildiz, Ismail Yilmaz, Sevilay Akalp Özmen, Diren Vuslat Çağatay, Itır Ebru Zemheri, Murat Demiriz, Armağan Günal Journal of Environmental Pathology, Toxicology and Oncology.2023; 42(4): 1. CrossRef
Clinicopathologic and Molecular Characterization of Anorectal Neuroendocrine Carcinomas Reveals Human Papillomavirus, p53, and c-Myc as Alternative Mechanisms of Carcinogenesis Allison J. Cox, William E. Crowe, Qi Yang, Bin Zhang, Zoltán N. Oltvai, Xiaoyan Liao Modern Pathology.2023; 36(11): 100295. CrossRef
Dedifferentiated Endometrial Carcinoma: A Rare Aggressive Neoplasm-Clinical, Morphological and Immunohistochemical Features Giovanna Giordano, Elena Ferioli, Debora Guareschi, Alessandro Tafuni Cancers.2023; 15(21): 5155. CrossRef
Characterization on the oncogenic effect of the missense mutations of p53 via machine learning Qisheng Pan, Stephanie Portelli, Thanh Binh Nguyen, David B Ascher Briefings in Bioinformatics.2023;[Epub] CrossRef
Adrenal Nodules Detected at Staging CT in Patients with Resectable Gastric Cancers Have a Low Incidence of Malignancy Hae Young Kim, Won Chang, Yoon Jin Lee, Ji Hoon Park, Jungheum Cho, Hee Young Na, Hyungwoo Ahn, Sung Il Hwang, Hak Jong Lee, Young Hoon Kim, Kyoung Ho Lee Radiology.2022; 302(1): 129. CrossRef
Dedifferentiation-like tubular and solid carcinoma of the stomach shows phenotypic divergence and association with deficient SWI/SNF complex Shih-Chiang Huang, Kuang-Hua Chen, Kwai-Fong Ng, I-Chieh Lin, Yi-Chun Chao, Ta-Sen Yeh, Huei-Chieh Chuang, Tse-Ching Chen Virchows Archiv.2022; 480(4): 771. CrossRef
Distinct molecular phenotype and the potential prognostic value of immune prognostic index and tumor infiltrating lymphocytes in hepatoid adenocarcinoma of stomach Muxing Kang, Xiaojing Ma, Jifei Shi, Guofeng Chen, Xiaoli Jin, Jun Wang, Lele Lin, Zhiwei Wu, Kaibo Chen, Jinghong Xu, Pintong Huang, Jian Chen Translational Oncology.2022; 19: 101380. CrossRef
Evaluation of Tumor DNA Sequencing Results in Patients with Gastric and Gastroesophageal Junction Adenocarcinoma Stratified by TP53 Mutation Status Anthony C Wood, Yonghong Zhang, Qianxing Mo, Ling Cen, Jacques Fontaine, Sarah E Hoffe, Jessica Frakes, Sean P Dineen, Jose M Pimiento, Christine M Walko, Rutika Mehta The Oncologist.2022; 27(4): 307. CrossRef
Comprehensive Clinical Analysis of Gallbladder Neuroendocrine Neoplasms: A Large-Volume Multicenter Study During One Decade Yangyang Wang, Bingfeng Huang, Qihan Fu, Jianing Wang, Mao Ye, Manyi Hu, Kai Qu, Kai Liu, Xiao Hu, Shumei Wei, Ke Sun, Wenbo Xiao, Bo Zhang, Haijun Li, Jingsong Li, Qi Zhang, Tingbo Liang Annals of Surgical Oncology.2022; 29(12): 7619. CrossRef
Expression of SASP, DNA Damage Response, and Cell Proliferation Factors in Early Gastric Neoplastic Lesions: Correlations and Clinical Significance Li Liang, Yijie Chai, Fei Chai, Haijing Liu, Ningning Ma, Hong Zhang, Shuang Zhang, Lin Nong, Ting Li, Bo Zhang Pathology and Oncology Research.2022;[Epub] CrossRef
Systems biology and OMIC data integration to understand gastrointestinal cancers Iasmin Moreira Costa Bispo, Henry Paul Granger, Palloma Porto Almeida, Patricia Belini Nishiyama, Leandro Martins de Freitas World Journal of Clinical Oncology.2022; 13(10): 762. CrossRef
MicroRNA-552 expression in colorectal cancer and its clinicopathological significance Joon Im, Soo Kyung Nam, Hye Seung Lee Journal of Pathology and Translational Medicine.2021; 55(2): 125. CrossRef
Different effects of p53 protein overexpression on the survival of gastric cancer patients according to Lauren histologic classification: a retrospective study Ki Wook Kim, Nayoung Kim, Yonghoon Choi, Won Seok Kim, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Dong Ho Lee, Young Suk Park, Sang-Hoon Ahn, Do Joong Park, Hyung-Ho Kim, Hye Seung Lee, Ji-Won Kim, Jin Won Kim, Keun-Wook Lee, Won Chang, Ji Hoon Park, Yoon Gastric Cancer.2021; 24(4): 844. CrossRef
The association between the expression of nuclear Yes-associated protein 1 (YAP1) and p53 protein expression profile in breast cancer patients Yoon Jin Cha, Dooreh Kim, Soong June Bae, Sung Gwe Ahn, Joon Jeong, Min Kyung Cho, Pill Sun Paik, Tae-Kyung Yoo, Woo-Chan Park, Chang Ik Yoon, Elda Tagliabue PLOS ONE.2021; 16(5): e0250986. CrossRef
Yangkyu Lee, Hyunjin Park, Hyejung Lee, Jai Young Cho, Yoo-Seok Yoon, Young-Rok Choi, Ho-Seong Han, Eun Sun Jang, Jin-Wook Kim, Sook-Hyang Jeong, Soomin Ahn, Haeryoung Kim
J Pathol Transl Med. 2018;52(2):85-92. Published online November 24, 2017
Background We aimed to determine the clinicopathological significance of the gross classification of hepatocellular carcinoma (HCC) according to the Korean Liver Cancer Association (KLCA) guidelines.
Methods A retrospective analysis was performed on 242 cases of consecutively resected solitary primary HCC between 2003 and 2012 at Seoul National University Bundang Hospital. The gross classification (vaguely nodular [VN], expanding nodular [EN], multinodular confluent [MC], nodular with perinodular extension [NP], and infiltrative [INF]) was reviewed for all cases, and were correlated with various clinicopathological features and the expression status of “stemness”-related (cytokeratin 19 [CK19], epithelial cell adhesion molecule [EpCAM]), and epithelial-mesenchymal transition (EMT)–related (urokinase plasminogen activator receptor [uPAR] and Ezrin) markers.
Results Significant differences were seen in overall survival (p=.015) and disease-free survival (p = .034) according to the gross classification; INF type showed the worst prognosis while VN and EN types were more favorable. When the gross types were simplified into two groups, type 2 HCCs (MC/NP/INF) were more frequently larger and poorly differentiated, and showed more frequent microvascular and portal venous invasion, intratumoral fibrous stroma and higher pT stages compared to type 1 HCCs (EN/VN) (p<.05, all). CK19, EpCAM, uPAR, and ezrin expression was more frequently seen in type 2 HCCs (p<.05, all). Gross classification was an independent predictor of both overall and disease-free survival by multivariate analysis (overall survival: p=.030; hazard ratio, 4.118; 95% confidence interval, 1.142 to 14.844; disease-free survival: p=.016; hazard ratio, 1.617; 95% confidence interval, 1.092 to 2.394).
Conclusions The gross classification of HCC had significant prognostic value and type 2 HCCs were associated with clinicopathological features of aggressive behavior, increased expression of “stemness”- and EMT-related markers, and decreased survival.
Citations
Citations to this article as recorded by
Association between tumor morphology and efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma Nobuaki Ishihara, Shohei Komatsu, Keitaro Sofue, Eisuke Ueshima, Yoshihiko Yano, Yoshimi Fujishima, Jun Ishida, Masahiro Kido, Hidetoshi Gon, Kenji Fukushima, Takeshi Urade, Hiroaki Yanagimoto, Hirochika Toyama, Yoshihide Ueda, Yuzo Kodama, Takamichi Mura Hepatology Research.2024; 54(8): 773. CrossRef
Macroscopic Characterization of Hepatocellular Carcinoma: An Underexploited Source of Prognostic Factors Stéphanie Gonvers, Sebastiao Martins-Filho, André Hirayama, Julien Calderaro, Rebecca Phillips, Emilie Uldry, Nicolas Demartines, Emmanuel Melloul, Young Nyun Park, Valérie Paradis, Swan Thung, Venancio Alves, Christine Sempoux, Ismail Labgaa Journal of Hepatocellular Carcinoma.2024; Volume 11: 707. CrossRef
Serum Total Superoxide Dismutase Activity as a Predictive Factor in Patients with Hepatocellular Carcinoma Yanqiu Xu, Bin Liu, Shiqing Cheng, Junguo Zhang, Xiue Cao, Yong Wang, Fang Luan Hepatitis Monthly.2024;[Epub] CrossRef
Diagnostic value of expressions of cancer stem cell markers for adverse outcomes of hepatocellular carcinoma and their associations with prognosis: A Bayesian network meta‑analysis Zhengrong Ou, Shoushuo Fu, Jian Yi, Jingxuan Huang, Weidong Zhu Oncology Letters.2024;[Epub] CrossRef
Recurrence of hepatocellular carcinoma in noncirrhotic patients with nonalcoholic fatty liver disease versus hepatitis B infection Jungnam Lee, Jong-In Chang, Young-Joo Jin, Jeong-Hoon Lee, Ju Yeon Kim, Dong Hyun Sinn, Soon Sun Kim, Hyun Woong Lee, Sun Hong Yoo, Jung Hwan Yu, Jin-Woo Lee European Journal of Gastroenterology & Hepatology.2023; 35(4): 431. CrossRef
Comprehensive investigating of MMR gene in hepatocellular carcinoma with chronic hepatitis B virus infection in Han Chinese population Ning Ma, Ao Jin, Yitong Sun, Yiyao Jin, Yucheng Sun, Qian Xiao, XuanYi Sha, Fengxue Yu, Lei Yang, Wenxuan Liu, Xia Gao, Xiaolin Zhang, Lu Li Frontiers in Oncology.2023;[Epub] CrossRef
LI-RADS Morphological Type Predicts Prognosis of Patients with Hepatocellular Carcinoma After Radical Resection Chunhui Zhang, Rui Yang, Xinxin Wang, Yuqing Tao, Shuli Tang, Zhennan Tian, Yang Zhou Annals of Surgical Oncology.2023; 30(8): 4876. CrossRef
From clinical variables to multiomics analysis: a margin morphology-based gross classification system for hepatocellular carcinoma stratification Zhongqi Fan, Meishan Jin, Lei Zhang, Nanya Wang, Mingyue Li, Chuanlei Wang, Feng Wei, Ping Zhang, Xiaohong Du, Xiaodong Sun, Wei Qiu, Meng Wang, Hongbin Wang, Xiaoju Shi, Junfeng Ye, Chao Jiang, Jianpeng Zhou, Wengang Chai, Jun Qi, Ting Li, Ruoyan Zhang, Gut.2023; 72(11): 2149. CrossRef
A clinical and pathological update on hepatocellular carcinoma Salvatore Lorenzo Renne, Luca Di Tommaso Journal of Liver Cancer.2022; 22(1): 14. CrossRef
An approach to grossing of hepatectomy specimens Archana Rastogi Indian Journal of Pathology and Microbiology.2021; 64(5): 121. CrossRef
Hepatocellular carcinoma: a clinical and pathological overview Salvatore Lorenzo Renne, Samantha Sarcognato, Diana Sacchi, Maria Guido, Massimo Roncalli, Luigi Terracciano, Luca Di Tommaso Pathologica.2021; 113(3): 203. CrossRef
The Clinicopathological Significance of YAP/TAZ Expression in Hepatocellular Carcinoma with Relation to Hypoxia and Stemness Hyunjin Park, Yangkyu Lee, Kiryang Lee, Hyejung Lee, Jeong Eun Yoo, Soomin Ahn, Young Nyun Park, Haeryoung Kim Pathology and Oncology Research.2021;[Epub] CrossRef
Adjuvant versus Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: Clinical and Immunologic Perspectives Yung-Yeh Su, Chia-Chen Li, Yih-Jyh Lin, Chiun Hsu Seminars in Liver Disease.2021; 41(03): 263. CrossRef
Prognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment Yoon Jung Hwang, Youngeun Lee, Hyunjin Park, Yangkyu Lee, Kyoungbun Lee, Haeryoung Kim Journal of Pathology and Translational Medicine.2021; 55(5): 338. CrossRef
Survival according to recurrence patterns after resection for transplantable hepatocellular carcinoma in HBV endemic area: Appraisal of liver transplantation strategy Chung Gyo Seo, Sun Young Yim, Soon Ho Um, Yoo Ra Lee, Yoo Jin Lee, Tae Hyung Kim, Hyun Gil Goh, Young Sun Lee, Sang Jun Suh, Na Yeon Han, Hyuk Soon Choi, Eun Sun Kim, Bora Keum, Yeon Seok Seo, Hyung Joon Yim, Ji Hoon Kim, Dong Sik Kim, Yoon Tae Jeen, Hoon Clinics and Research in Hepatology and Gastroenterology.2020; 44(4): 532. CrossRef
A radiomics-based biomarker for cytokeratin 19 status of hepatocellular carcinoma with gadoxetic acid–enhanced MRI Wentao Wang, Dongsheng Gu, Jingwei Wei, Ying Ding, Li Yang, Kai Zhu, Rongkui Luo, Sheng-Xiang Rao, Jie Tian, Mengsu Zeng European Radiology.2020; 30(5): 3004. CrossRef
Paeonol Inhibits Cell Proliferation, Migration and Invasion and Induces Apoptosis in Hepatocellular Carcinoma by Regulating miR-21-5p/KLF6 Axis
Miaoguo Cai, Wei Shao, Huijun Yu, Ye Hong, Lili Shi Cancer Management and Research.2020; Volume 12: 5931. CrossRef
Update on Hepatocellular Carcinoma: a Brief Review from Pathologist Standpoint Nese Karadag Soylu Journal of Gastrointestinal Cancer.2020; 51(4): 1176. CrossRef
Clinico-Radio-Pathological and Molecular Features of Hepatocellular Carcinomas with Keratin 19 Expression Hyungjin Rhee, Haeryoung Kim, Young Nyun Park Liver Cancer.2020; 9(6): 663. CrossRef
Histopathological characteristics of needle core biopsy and surgical specimens from patients with solitary hepatocellular carcinoma or intrahepatic cholangiocarcinoma Ju-Shan Wu, Ji-Liang Feng, Rui-Dong Zhu, San-Guang Liu, Da-Wei Zhao, Ning Li World Journal of Gastrointestinal Oncology.2019; 11(5): 404. CrossRef
The strengths and weaknesses of gross and histopathological evaluation in hepatocellular carcinoma: a brief review Sebastião N. Martins-Filho, Venâncio Avancini Ferreira Alves Surgical and Experimental Pathology.2019;[Epub] CrossRef
Changing role of histopathology in the diagnosis and management of hepatocellular carcinoma Archana Rastogi World Journal of Gastroenterology.2018; 24(35): 4000. CrossRef
Background There is increasing interest in hepatocellular carcinomas (HCC) expressing “stemness”-related markers, as they have been associated with aggressive behavior and poor prognosis. In this study, we investigated the usefulness of Sal-like protein 4 (SALL4), a recently proposed candidate marker of “stemness.” Methods: Immunohistochemical stains were performed for SALL4, K19, and epithelial cellular adhesion molecule (EpCAM) on tissue microarrays constructed from 190 surgically resected HCCs, and the results were correlated with the clinicopathological features and patient survival data. Results: Nuclear SALL4 expression was observed in 39/190 HCCs (20.5%), while K19 and EpCAM were expressed in 30 (15.9%) and 92 (48.7%) HCCs, respectively. The nuclear expression was generally weak, punctate or clumped. SALL4 expression was significantly associated with a poor overall survival compared to SALL4-negative HCCs (p = .014) compared to SALL4-negative HCCs. On multivariate analysis adjusted for tumor size, multiplicity, vascular invasion, and pathological tumor stage, SALL4 remained as a significant independent predictor of decreased overall survival (p= .004). SALL4 expression was positively correlated with EpCAM expression (p = .013) but not with K19 expression. HCCs that expressed both SALL4 and EpCAM were associated with significantly decreased overall survival, compared to those cases which were negative for both of these markers (p = .031). Conclusions: Although SALL4 expression was not significantly correlated with other clinicopathological parameters suggestive of tumor aggressiveness, SALL4 expression was an independent predictor of poor overall survival in human HCCs, and was also positively correlated with EpCAM expression.
Citations
Citations to this article as recorded by
Stemness markers in hepatocellular carcinoma of Eastern vs. Western population: Etiology matters? Caecilia HC Sukowati, Korri El-Khobar, Chyntia Olivia Maurine Jasirwan, Juferdy Kurniawan, Rino Alvani Gani Annals of Hepatology.2024; 29(1): 101153. CrossRef
Research progress and prospects of AFP-positive gastric cancer Long Zhao, Changjiang Yang, Yilin Lin, Shan Wang, Yingjiang Ye, Zhanlong Shen Foregut Surgery.2022; 2(1): 29. CrossRef
SALL4 and microRNA: The Role of Let-7 Jun Liu, Madeline A. Sauer, Shaza G. Hussein, Junyu Yang, Daniel G. Tenen, Li Chai Genes.2021; 12(9): 1301. CrossRef
Hepatoid Teratoma, Hepatoid Yolk Sac Tumor, and Hepatocellular Carcinoma Khaleel I. Al-Obaidy, Sean R. Williamson, Nathan Shelman, Muhammad T. Idrees, Thomas M. Ulbright American Journal of Surgical Pathology.2021; 45(1): 127. CrossRef
Targeting an Inducible SALL4-Mediated Cancer Vulnerability with Sequential Therapy Junyu Yang, Chong Gao, Miao Liu, Yao-Chung Liu, Junsu Kwon, Jun Qi, Xi Tian, Alicia Stein, Yanjing V. Liu, Nikki R. Kong, Yue Wu, Shenyi Yin, Jianzhong Xi, Zhiyuan Chen, Kalpana Kumari, Hannan Wong, Hongbo Luo, Leslie E. Silberstein, Julie A.I. Thoms, Ash Cancer Research.2021; 81(23): 6018. CrossRef
Lipoprotein‐Like Nanoparticle Carrying Small Interfering RNA Against Spalt‐Like Transcription Factor 4 Effectively Targets Hepatocellular Carcinoma Cells and Decreases Tumor Burden William Cruz, Huang Huang, Brian Barber, Elisa Pasini, Lili Ding, Gang Zheng, Juan Chen, Mamatha Bhat Hepatology Communications.2020; 4(5): 769. CrossRef
Hepatoid adenocarcinoma of the stomach: a unique subgroup with distinct clinicopathological and molecular features Yakun Wang, Li Sun, Zhongwu Li, Jing Gao, Sai Ge, Cheng Zhang, Jiajia Yuan, Xicheng Wang, Jian Li, Zhihao Lu, Jifang Gong, Ming Lu, Jun Zhou, Zhi Peng, Lin Shen, Xiaotian Zhang Gastric Cancer.2019; 22(6): 1183. CrossRef
Gynecologic Serous Carcinoma: An Immunohistochemical Analysis of Malignant Body Fluid Specimens Shuyue Ren, William Klump Archives of Pathology & Laboratory Medicine.2019; 143(6): 677. CrossRef
The Pluripotency Network in Colorectal Cancer Pathogenesis and Prognosis: an Update Ioannis A Voutsadakis Biomarkers in Medicine.2018; 12(6): 653. CrossRef
Cancer stem cells in hepatocellular carcinoma: an overview and promising therapeutic strategies Nuozhou Wang, Shanshan Wang, Ming-Yue Li, Bao-guang Hu, Li-ping Liu, Sheng-li Yang, Shucai Yang, Zhongqin Gong, Paul B. S. Lai, George G. Chen Therapeutic Advances in Medical Oncology.2018;[Epub] CrossRef
DNA demethylation induces SALL4 gene re-expression in subgroups of hepatocellular carcinoma associated with Hepatitis B or C virus infection H Fan, Z Cui, H Zhang, S K Mani, A Diab, L Lefrancois, N Fares, P Merle, O Andrisani Oncogene.2017; 36(17): 2435. CrossRef
Higher expression of SALL4 predicts poor cancer prognosis: A meta-analysis Hongyu Shen, Liangpeng Li, Dandan Wang, Sujin Yang, Xiu Chen, Siying Zhou, Shanliang Zhong, Jianhua Zhao, Jinhai Tang Cancer Biomarkers.2017; 19(4): 365. CrossRef
SALL4 suppresses PTEN expression to promote glioma cell proliferation via PI3K/AKT signaling pathway Chuanjin Liu, Haibin Wu, Yanyan Li, Liang Shen, Renchun Yu, Hongwei Yin, Ting Sun, Chunming Sun, Youxin Zhou, Ziwei Du Journal of Neuro-Oncology.2017; 135(2): 263. CrossRef
Liver Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells Germana Castelli, Elvira Pelosi, Ugo Testa Cancers.2017; 9(9): 127. CrossRef
Oncofetal gene SALL4 and prognosis in cancer: A systematic review with meta-analysis Lorenzo Nicolè, Tiziana Sanavia, Nicola Veronese, Rocco Cappellesso, Claudio Luchini, Paolo Dabrilli, Ambrogio Fassina Oncotarget.2017; 8(14): 22968. CrossRef
SALL4, the missing link between stem cells, development and cancer Hiro Tatetsu, Nikki R. Kong, Gao Chong, Giovanni Amabile, Daniel G. Tenen, Li Chai Gene.2016; 584(2): 111. CrossRef
A New Cell Block Method for Multiple Immunohistochemical Analysis of Circulating Tumor Cells in Patients with Liver Cancer Soo Jeong Nam, Hyun Yang Yeo, Hee Jin Chang, Bo Hyun Kim, Eun Kyung Hong, Joong-Won Park Cancer Research and Treatment.2016; 48(4): 1229. CrossRef
Functional and clinical significance of SALL4 in breast cancer Ebubekir Dirican, Mustafa Akkiprik Tumor Biology.2016; 37(9): 11701. CrossRef
MicroRNA-33b suppresses the proliferation and metastasis of hepatocellular carcinoma cells through the inhibition of Sal-like protein 4 expression Qinggang Tian, Yao Xiao, Yanting Wu, Yun Liu, Zhiqing Song, Wenfeng Gao, Jing Zhang, Jingling Yang, Yuguo Zhang, Tuankui Guo, Furong Dai, Zhigang Sun International Journal of Molecular Medicine.2016; 38(5): 1587. CrossRef
Oncogenic protein SALL4 and ZNF217 as prognostic indicators in solid cancers: a meta-analysis of individual studies Ji Cheng, Jinbo Gao, Xiaoming Shuai, Kaixiong Tao Oncotarget.2016; 7(17): 24314. CrossRef